Phio Pharmaceuticals Corp. (PHIO) has a negative trailing P/E of -1.7, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -59.66%.
Criteria proven by this page:
Overall SharesGrow Score: 64/100 with 4/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -0.5 | 0.04 | 0.44 | 253.47 | - |
| 2017 | -1.0 | 0.02 | 6.84 | 835.53 | - |
| 2018 | -0.3 | 0.00 | 0.17 | 16.81 | - |
| 2019 | -0.5 | 0.01 | 0.75 | 206.17 | - |
| 2020 | -1.4 | 0.02 | 0.95 | 0.00 | - |
| 2021 | -1.0 | 0.02 | 0.58 | 0.00 | - |
| 2022 | -0.4 | 0.02 | 0.47 | 0.00 | - |
| 2023 | -0.1 | 0.00 | 0.20 | 0.00 | - |
| 2024 | -0.2 | 0.00 | 0.30 | 0.00 | - |
| 2025 | -0.7 | -0.01 | 0.31 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-79,282.80 | $19K | $-8.99M | -47336.8% |
| 2017 | $-32,801.20 | $15K | $-12.45M | -83013.3% |
| 2018 | $-6,218.35 | $138K | $-7.36M | -5333.3% |
| 2019 | $-2,074.18 | $21K | $-8.84M | -42100% |
| 2020 | $-207.25 | $0.00 | $-8.79M | - |
| 2021 | $-111.32 | $0.00 | $-13.21M | - |
| 2022 | $-89.61 | $0.00 | $-11.31M | - |
| 2023 | $-46.76 | $0.00 | $-10.83M | - |
| 2024 | $-0.91 | $0.00 | $-7.15M | - |
| 2025 | $-1.45 | $0.00 | $-8.7M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.95 | $-1.01 – $-0.89 | $0.00 | $0.00 – $0.00 | 2 |
| 2027 | $-0.62 | $-0.75 – $-0.49 | $0.00 | $0.00 – $0.00 | 2 |
